MedTrace Logo

Ivermectin Nasal Drops in Post COVID-19 Parosmia

NCT05269030 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-05-11

No results posted yet for this study

Summary

The current study will be a pilot study for a randomized controlled trial conducted on patients recruited from the outpatient clinic of the Otorhinolaryngology Department, Menoufia Faculty of Medicine To evaluate the effect of ivermectin nasal drops in the treatment of post COVID 19 parosmia

Conditions

  • Parosmia

Interventions

DRUG

Ivermectin Topical

Ivermectin 1% in a dose of two drops per nostril twice daily.

DRUG

Budesonide Nasal

64 µg per puff in a dose of 1 puff for each nostril twice daily.

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05269030 on ClinicalTrials.gov